Literature DB >> 33689572

Serum Biomarkers in Neuro-Ophthalmology: When to Test.

Devon A Cohen1,2, Ryan Gise1,2,3, Eric D Gaier1,2,3,4.   

Abstract

Discovery and characterization of serologic biomarkers has revolutionized the diagnostic framework of systemic and paraneoplastic autoimmune neuro-ophthalmic diseases. Expanding recognition of the multiple ocular and visual manifestations of these conditions highlights the important role of the referring provider in identifying potential cases. Increasing ease of access to serologic testing also enables these practitioners to initiate the diagnostic work-up in suspected cases. We aimed to provide an update on the current knowledge surrounding and use of relevant autoimmune biomarkers by correlating specific clinical neuro-ophthalmic manifestations with autoantibody biomarkers. The utility of select biomarkers for myasthenia gravis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein-IgG-associated disorder, opsoclonus-myoclonus syndrome, anti-collapsin-response mediator protein-5 optic neuropathy, and glial fibrillary acidic protein-IgG-associated disease are discussed with particular focus on the clinical contexts in which to consider testing.

Entities:  

Keywords:  Autoantibodies; autoimmune neuro-ophthalmic disorders; neuro-ophthalmology; paraneoplastic syndromes; serum biomarkers

Year:  2021        PMID: 33689572     DOI: 10.1080/08820538.2021.1897856

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  1 in total

1.  Serum and Cerebrospinal Fluid Testing in Optic Neuropathy Patients with Malignant Tumors.

Authors:  Chuan-Bin Sun; Geng-Hao Liu; Qing Xiao; Yi-Nv Zhao; Qian Ren
Journal:  Dis Markers       Date:  2022-02-17       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.